340B-Where Do We Go From Here?

Sanjay Kishore^{1

2}, Rahul K Nayak³, Aaron S Kesselheim^{4

5}

Affiliations

¹ The Equal Justice Initiative, Montgomery, Alabama.
² The University of Alabama at Birmingham.
³ Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
⁴ Program on Regulation, Therapeutics, and Law (PORTAL), Brigham and Women's Hospital, Boston, Massachusetts.
⁵ Harvard Medical School, Boston, Massachusetts.

Sanjay Kishore et al. JAMA. 2023.

. 2023 Aug 15;330(7):593-594.

doi: 10.1001/jama.2023.11056.

Sanjay Kishore^{1

2}, Rahul K Nayak³, Aaron S Kesselheim^{4

5}

¹ The Equal Justice Initiative, Montgomery, Alabama.
² The University of Alabama at Birmingham.
³ Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
⁴ Program on Regulation, Therapeutics, and Law (PORTAL), Brigham and Women's Hospital, Boston, Massachusetts.
⁵ Harvard Medical School, Boston, Massachusetts.

No abstract available

Plain language summary

This Viewpoint summarizes inefficiencies in the 340B program and provides suggestions for equitable reform that will potentially benefit patients.